Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

N. Fader, Amanda; M. Roque, Dana; R. Siegel, Eric; Buza, Natália; Hui, Pei; Abdelghany, Osama; K. Chambers, Setsuko; Alvarez Secord, Angeles; J. Havrilesky, Laura; M. O’Malley, David; Backes, Floor; Nevadunsky, Nicole; Edraki, Babak; Pikaart, Dirk; J. Lowery, William; ElSahwi, Karim; Celano, Paul; Bellone, Stefania; Azodi, Masoud; Litkouhi, Babak; Ratner, Elena; Silasi, Dan-Arin; E. Schwartz, Peter; D. Santin, Alessandro

doi:10.1158/1078-0432.ccr-20-0953

Public

Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

Published in Clinical Cancer Research • Jun 29, 2020

Authors:

Amanda N. Fader

Dana M. Roque

Eric R. Siegel

Abstract

Abstract Purpose: Uterine-serous-carcinoma (USC) is an aggressive variant of endometrial cancer. On the basis of preliminary results of a multicenter, randomized phase II trial, trastuzumab (T), a humanized-mAb targeting Her2/Neu, in combination with carboplatin/paclitaxel (C/P), is recognized as an...

Subject

Medicine

Carboplatin

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!